NASDAQ:GOSS

Gossamer Bio Stock Predictions

etoro logo Buy GOSS
*Your capital is at risk
$0.188
-0.0119 (-5.94%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

GOSS Prediction Chart

GOSS Predictions History

Latest community submissions for GOSS.
Predictor Target Session Target Price Result Direction Accuracy Score
JS JS Pro
Aug 16, 2021 $9.05 +9.70% $8.25 X 90.30% 0
Aug 16, 2021 Bullish $8.25 X 0
JS JS Pro
Feb 23, 2021 $10.91 +8.13% $10.09 X 91.87% 1
alex kiza alex kiza @alexkiza.209830
Feb 23, 2021 Bullish $10.09 X 0
JS JS Pro
Feb 22, 2021 $10.94 +0.00% $10.94 X 99.95% 10
Bradon VanWinkle Bradon VanWinkle @BradonVanWinkle.208773
Feb 22, 2021 Bearish $10.94 V 0
sander7100 yo bro sander7100 yo bro Pro @sander7100yobro.167552
Feb 18, 2021 $10.88 +3.23% $10.54 X 96.77% 0
נגה קיטרון נגה קיטרון @D7A0D792D794D7A7D799D798D7A8D795D79F.212272
Feb 18, 2021 Bullish $10.54 X 0
JS JS Pro
Feb 18, 2021 $10.96 +3.98% $10.54 X 96.02% 0
JS JS Pro
Feb 17, 2021 $10.83 -0.46% $10.88 X 99.59% 5
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for GOSS with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT GOSSAMER BIO INC.
Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hy...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE